- Home
- CNEY vs INBS Comparison
CNEY vs INBS Comparison
Compare CNEY & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNEY | INBS |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 6.4M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CNEY | INBS |
|---|---|---|
| Price | $0.82 | $4.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 136.1K | 79.6K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 68.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,980,484.00 |
| Revenue This Year | N/A | $778.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $0.54 |
| 52 Week High | $3.25 | $24.90 |
Technical Indicators
Market Signals| Indicator | CNEY | INBS |
|---|---|---|
| Relative Strength Index (RSI) | 38.56 | 36.92 |
| Support Level | $0.54 | $3.87 |
| Resistance Level | $1.10 | $7.25 |
| Average True Range (ATR) | 0.10 | 0.49 |
| MACD | -0.03 | 0.12 |
| Stochastic Oscillator | 10.22 | 30.43 |
Price Performance
Historical ComparisonAbout CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About INBS Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.